文献速递神经肿瘤

IDH突变型胶质瘤首次复发后进展加速

Accelerated progression of IDH mutant glioma after first recurrence.
PubMed 文献 · Neuro Oncol · 2019-01-01

该研究回顾性分析了275例IDH突变型胶质瘤患者,中位随访6.4年,中位首次无进展生存期(PFS1)为5.7年,中位总生存期(OS)为18.7年;首次进展后中位无进展生存期(PFS2)加速至3.1年,且PFS2可识别总生存更差的患者。

要点

  • IDH突变型胶质瘤患者中位PFS1为5.7年,中位OS为18.7年。
  • 首次进展后中位PFS2为3.1年,短于PFS1,提示进展加速。
  • PFS2可作为识别总生存更差患者的替代预后标志物。

核心结论

  • IDH突变型胶质瘤首次复发后至第二次复发的时间(PFS2,3.1年)短于诊断至首次复发的时间(PFS1,5.7年),提示肿瘤从惰性病程转为加速恶性阶段。

研究设计与样本

  • 回顾性分析275例在本机构治疗的IDH突变型胶质瘤患者,采用神经肿瘤疗效评估中的低级别胶质瘤标准判定进展,用Kaplan-Meier法计算生存统计。

主要发现

  • 中位随访6.4年期间,观察到44例死亡(7.6%)和149例首次进展(PFS1)事件(54.1%)。
  • 中位PFS1为5.7年(95%CI:4.7-6.4),中位OS为18.7年(95%CI:12.2年-未达到)。
  • 观察到分级、分子诊断和治疗与PFS1相关。
  • 首次进展事件后,在中位随访4.1年期间发生79例第二次进展事件,中位PFS2加速至3.1年(95%CI:2.1-4.1)。
  • PFS2是替代预后标志物,可识别总生存更差的患者。

临床怎么用

  • 作者认为,PFS2是评估复发时药物疗效试验的相关结局指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in the World Health Organization (WHO) 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas. METHODS: We retrospectively analyzed 275 IDH mutant glioma patients treated at our institution. Progression was determined using low-grade glioma criteria from Response Assessment in Neuro-Oncology. We calculated survival statistics with the Kaplan-Meier method, and survival proportions were correlated with molecular, histologic, and clinical factors. RESULTS: During a median follow-up of 6.4 years, 44 deaths (7.6%) and 149 first progression (PFS1) events (54.1%) were observed. Median PFS1 was 5.7 years (95% CI: 4.7-6.4) and OS was 18.7 years (95% CI: 12.2 y-not reached). Consistent with prior studies, we observed an association of grade, molecular diagnosis, and treatment with PFS1. Following the first progressive episode, 79 second progression events occurred during a median follow-up period of 4.1 years. Median PFS following an initial progressive event (PFS2) was accelerated at 3.1 years (95% CI: 2.1-4.1). PFS2 was a surrogate prognostic marker, identifying patients with poorer overall survival. CONCLUSION: We report outcomes in a large cohort of IDH mutant glioma, providing a well-characterized historical control population for future clinical trial design. Notably, the interval between first and second recurrence (PFS2, 3.0 y) is shorter than time from diagnosis to first recurrence (PFS1, 5.7 y), evidence that these tumors clinically degenerate from an indolent course to an accelerated malignant phase. Thus, PFS2 represents a relevant outcome for trials investigating drug efficacy at recurrence.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Miller JJ, Loebel F, Juratli TA, et al. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019. PMID: 30668823. doi:10.1093/neuonc/noz016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。